Tag: prostate cancer

“Despite increasing adoption of active surveillance (AS) for low-risk prostate cancer, AS discontinuation rates are high, investigators report.” This quote, from a September 2021 Renal & Urology News report, referred to a study of over 16,000 Canadian prostate cancer (PCa) patients who had been diagnosed with low risk disease from 2008-2014. 51% of these patients keep reading

Men with localized prostate cancer (PCa) are usually given three treatment choices: radical prostatectomy (RP), external beam radiation therapy (EBRT) or Active Surveillance (AS). Although patients are rarely told about minimal-to-noninvasive treatments that can be applied as focal therapy... keep reading

Less than a year after we posted the original blog on the safety of testosterone replacement therapy (TRT) in the context of prostate cancer (PCa), a team from Baylor College of Medicine (Houston, TX) published the following statement: “The fears of [TRT] causing or worsening prostate cancer... keep reading

Advances in medicine sometimes involve hybrid technologies, often with stunning results. Just as hybrid cars produce vehicles that offer the best of two worlds in one, integrating two different medical imaging technologies can accomplish the same goal. PET and MRI scans Combining Positron Emitting Tomography (PET) scanning with Magnetic Resonance Imaging (MRI) boosts the accuracy keep reading

Getting an annual PSA blood test to screen for prostate cancer (PCa) has been likened to playing Russian roulette. You hope to dodge the you’ve-got-prostate-cancer bullet. So far, the search for a 100% accurate liquid biopsy via blood draw or urine test has been as unsuccessful as the hunt for a better mousetrap. keep reading

Prostate cancer is considered highly curable when it is detected early! This is also when a patient has the most treatment choices, including Active Surveillance and focal therapy with few to no side effects. The problem is, early stage prostate cancer is a silent lurker with no symptoms. However... keep reading

Over 1,200,000 men around the globe are diagnosed with prostate cancer (PCa) every year. They don’t all have the same disease, however. There are numerous cell lines with varying characteristics: “The disease is very heterogeneous in terms of grade, genetics, ploidy, and oncogene/tumor suppressor gene expression, and its biological, hormonal, and molecular characteristics are extremely keep reading

Up till now, prostate cancer has been the only tumor cancer diagnosed by random luck. That’s right, random luck. The most common type of prostate biopsy is guided by transrectal ultrasound, or TRUS. It is considered the “gold standard” for prostate biopsy because it’s most widely used by urologists... keep reading

Contrast agent Before addressing the title question regarding safety, it’s important to understand what a contrast agent does during MRI prostate imaging. Multiparametric MRI (mpMRI) of the prostate relies on two or more imaging sequences, or parameters, each of which depicts certain tissue characteristics that the others do not. When the results are synchronized, we keep reading

In the 5+ years since we posted the blog below, a new grading system called Gleason grade group has simplified the two-number system, which was confusing for patients. For example, in Gleason 7 prostate cancer (PCa), what’s the difference between... keep reading